Brandon Garcia, PharmD, PGY2


New Recommendations for Antibiotic Prophylaxis Prior to Dental Procedures

The American Dental Association (ADA) has updated patient profiles on who should be indicated for antibiotic prophylaxis.

Sarah Green, PharmD, BCPS, BCIDP, AAHIVP


Precision Dosing of To-Marrow: Linezolid Therapeutic Drug Monitoring

Emerging literature suggests therapeutic drug monitoring for this antimicrobial to minimize the risk for linezolid-associated toxicities while maintaining efficacy in select populations.

Theodore S. Rader IV, MD, MS


Will We Ever See Oral Carbapenems for ESBL Urinary Tract Infections?

Recent issues surrounding the ADAPT-PO and SURE-2 trials place the spotlight on the difficulties developing oral carbapenem-based antibiotics and case their future into doubt.

Christina Yen, MD; Ahmed Abdul Azim, MD; and Preeti Mehrotra, MD, MPH


From Single-Use to Multi-Use: A Brief Review of N95 Respirator Decontamination Strategies

This indispensable personal protective equipment did come up in short supply and reuse strategies has become a topic of great interest and research.

Nina Cosdon


Unveiling Gender Disparities in Lyme Disease: A Critical Analysis of Persistent Illness

Very few Lyme disease studies consider sex- and gender-based differences. Is this flawing the research?

Kaitlyn Jarrell, PharmD, BCPS, AAHIVP


PrEP State of the Union: Adherence, Access, Uptake Issues

Although this form of prophylaxis is highly protective, there are situations in which breakthrough infections occur.

Alyssa Walker, PharmD, BCPS, BCIDP


Antibiotic De-Escalation: Is This the Right Outcome Measure?

The proposed clinical benefits of de-escalation has contributed to its lukewarm adoption in some settings. This article looks at the challenges in measuring the impact of de-escalation, and the ongoing search for more meaningful metrics to evaluate the success of antimicrobial stewardship (AMS) programs.

Steven P. LaRosa, MD


Ceftriaxone as Definitive OPAT for MSSA Bloodstream Infections

A cautious approach for now is warranted as well as a need for a randomized clinical trial.

Geena Kludjian, PharmD, BCIDP


Employee Health After the COVID-19 Pandemic: Stronger Than Yesterday

For providers on the front lines, lessons learned can help inform strategies to enhance the protection of their health going forward.

Olivia Mobarakai, DO


Where Do We Draw the Line? Duration of Antibiotic Therapy Varies for Bloodstream Infections

With potential delays in treatment, bloodstream infections can be concerning for clinicians. Here is a review of the literature that offer guidance for treatment.

Victoria Grant, PharmD


Strengths and Limitations of T2Candida Implementation From an Antimicrobial Stewardship Perspective

This novel, rapid diagnostic assay uses polymerase chain reaction and magnetic resonance to identify the 5 most common Candida species.

Daniel Chastain, PharmD, BCIDP, AAHIVP


Clinical Considerations in Conducting Antifungal Susceptibility Testing

Access to antifungal susceptibility testing (AFST) remains limited in the United States. Therefore, providers must recognize clinical situations where AFST will provide its greatest value. In the latest article from SIDP, infectious disease pharmacists offers some insights on this subject.

Eunice Kim, PharmD


What Is a Better Treatment Approach for Immunocompromised Hosts With Clostridioides difficile Infection?

Here is a review of the effectiveness of fidaxomicin vs vancomycin for CDI treatment in populations with immunocompromised conditions.

Connor Iapoce


Weekly Flu Report Finds Sporadic Infections

This flu season, the CDC reported at least 2.4 million flu illnesses, 23,000 hospitalizations, and 1,400 deaths from flu so far.

Malki De Silva, MPH


Recent Research Indicates That We're Falling Short on HBV Elimination Targets

Organizations look at an agent-based model to assess the impact of vaccination, screening, and treatment on incidence and prevalence of HBV in Ontario, Canada.

Rick Starlin, MD


The Variety of Variants in COVID-19

The evolution of the major variants, including the delta mutation.

Kevin Michael Reiter, MD, PA


Practice Pearls for Treatment of Respiratory Infections

Tina Tan, MD; Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Priya Nori, MD; Jacinda Abdul-Mutakabbir, PharmD; and Kevin Michael Reiter, MD, PA, provide key takeaways from the discussion on the treatment of respiratory viral infections.

Victoria Johnson


HIV CRISPR Therapy Fast-Tracked by the FDA

The phase 1/2 trial evaluating EBT-101 dosed its first patient in September 2022.

Lauren Massaro


The US Will Transition to Trivalent Vaccines for Next Year's Influenza Season

Since changes in vaccine composition can sometimes lead to confusion or misinformation, effective communication is crucial to promote vaccine uptake.

Tracy Zembles, PharmD


Expanded Treatment Options for Multi-Drug Resistant Infections in Children

In the latest article from SIDP, here is a look at therapy options addressing this emerging clinical challenge.

Alexandra Hanretty, PharmD,


UTIs: Why Did You Have to Go and Make Things so Complicated?

Although hospitalizations due to urinary tract infections have increased, there are some investigational antibiotics in clinical trials. Here is a review of some of these therapies in the pipeline.

Westyn Branch-Elliman, MD, MMSc


From Pandemic to Endemic

A research agenda focusing on breakthrough infections, reinfections, severity, and sequelae is needed to inform clinical practice when COVID-19 emphasis shifts from eradication to living with the disease.

Celeste Krewson


FDA Approves Combination Antibiotic for Treatment of Complicated Urinary Tract Infections

Cefepime-enmetazobactam (Exblifep, Orchid Pharma) was given the federal nod for the indication of treating complicated urinary tract infections (cUTI) in adults.

Naasha Talati, MD


Community-Acquired Candida Glabrata Empyema: An Atypical Diagnosis Not to Miss

Although this patient had none of these common risk factors associated with Candida empyema, she did have other factors predisposing her to fungal colonization and subsequent infection.

Tanner Johnson, PharmD, AAHIVP


IV Push Administration for Outpatient Parenteral Antimicrobial Therapy

Investigators designed a quasi-experimental pre- and post-intervention analysis comparing a pre-intervention cohort receiving IV drip antibiotic infusion with a post-intervention cohort receiving IVP administration.

Patrick A. Ryscavage, MD


Barriers to Health Care Transition in Adolescents and Young Adults With Early Acquired HIV Infection

Unique challenges can affect the success of the shift from pediatric to adult care settings.

© 2024 MJH Life Sciences

All rights reserved.